Theralase Technologies Inc. (CVE:TLT)

PRESS RELEASE

published on 10/05/2023 at 13:00, 2 years 5 months ago

Theralase(R) Files US Patent for Enhanced Immunotherapy
PRESS RELEASE

published on 09/29/2023 at 13:00, 2 years 5 months ago

Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
PRESS RELEASE

published on 09/27/2023 at 13:00, 2 years 5 months ago

Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer
PRESS RELEASE

published on 09/21/2023 at 22:35, 2 years 6 months ago

Theralase(R) Grants Stock Options
PRESS RELEASE

published on 09/07/2023 at 10:30, 2 years 6 months ago

Theralase(R) Closes Private Placement Equity Financing
PRESS RELEASE

published on 08/29/2023 at 22:30, 2 years 6 months ago

Theralase Release’s 2Q2023 Interim Financial Statements
PRESS RELEASE

published on 06/30/2023 at 22:35, 2 years 8 months ago

Theralase(R) Closes Non-Brokered Private Placement Equity Financing
PRESS RELEASE

published on 06/06/2023 at 13:00, 2 years 9 months ago

Theralase(R) Announces Appointment of New Independent Director
PRESS RELEASE

published on 05/31/2023 at 03:30, 2 years 9 months ago

Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
PRESS RELEASE

published on 05/31/2023 at 01:35, 2 years 9 months ago

Theralase(R) Releases 1Q2023 Interim Financial Statements

Published on 03/25/2026 at 18:53, 6 hours 21 minutes ago

LNA SANTE : 2025 Annual Results
Published on 03/25/2026 at 18:31, 6 hours 43 minutes ago

Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 7 hours 30 minutes ago

Combined General Meeting on May 05, 2026: publication of the notice of Meeting
Published on 03/25/2026 at 17:45, 7 hours 30 minutes ago

GUILLEMOT CORPORATION: 2025 ANNUAL RESULTS
Published on 03/25/2026 at 17:42, 7 hours 33 minutes ago

2025/2026 Second quarter Sales

News